Skip to main content

Clinical Trials Using Cytarabine

Review the clinical trials studying cytarabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 98

Testing New Therapies for Patients with Acute Myeloid Leukemia Who are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Status: Active
Location: 210 locations
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Status: Active
Location: 197 locations
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Status: Active
Location: 180 locations
Comparing Cytarabine + Daunorubicin Therapy versus Cytarabine + Daunorubicin + Venetoclax versus Venetoclax + Azacitidine in Younger Patients with Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Status: Active
Location: 171 locations
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia
Status: Active
Location: 409 locations
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 205 locations
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment with Blinatumomab for Children, Adolescents, and Young Adults with Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 142 locations
Testing the use of Daratumumab-Hyaluronidase in Persistent or Recurrent T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) following Treatment with Chemotherapy
Status: Active
Location: 128 locations
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants with Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Status: Active
Location: 113 locations
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, “7+3”) for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
Status: Active
Location: 39 locations
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Status: Active
Location: 34 locations
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status: Active
Location: 26 locations
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Status: Active
Location: 29 locations
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Status: Active
Location: 23 locations
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Status: Active
Location: 22 locations
A Study to find the Highest Dose of Imetelstat in Combination with Fludarabine and Cytarabine for Patients with AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Status: Active
Location: 19 locations
BRAZAN Induction Therapy Followed by Zanubrutinib and Rituximab Maintenance Therapy with or without Sonrotoclax for the Treatment of Mantle Cell Lymphoma
Status: Active
Location: 17 locations
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Status: Active
Location: 15 locations
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Status: Active
Location: 15 locations
Cytarabine or Vinblastine Sulfate and Prednisone in Treating Patients with Langerhans Cell Histocytosis
Status: Active
Location: 11 locations
Total Therapy for Infants with Acute Lymphoblastic Leukemia, The TINI 2 Study
Status: Active
Location: 10 locations
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Status: Active
Location: 11 locations
Revumenib, Azacitidine, and Venetoclax for the Treatment of Pediatric and Young Adult Patients with Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
Status: Active
Location: 10 locations
Talazoparib in Combination with Chemotherapy for the Treatment of Pediatric Patients with Relapsed or Refractory AML, the PARPAML Trial
Status: Active
Location: 10 locations
Chemotherapy with Radiation Therapy or Autologous Stem Cell Rescue for the Treatment of Embryonal Tumor with Multilayered Rosettes in Patients with Gross-Total Resection, Residual Disease, or Metastatic Disease
Status: Active
Location: 8 locations